HC Wainwright Has Positive Forecast for TVRD FY2026 Earnings

Tvardi Therapeutics, Inc. (NASDAQ:TVRD – Free Report) – HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of Tvardi Therapeutics in a research note issued to investors on Friday, November 13th. HC Wainwright analyst S. Nik now forecasts that the company will post earnings per share of ($2.32) for the year, up from their previous estimate of ($2.56). The consensus estimate for Tvardi Therapeutics’ current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for Tvardi Therapeutics’ Q4 2026 earnings at ($0.50) EPS, FY2027 earnings at ($1.51) EPS and FY2028 earnings at ($1.56) EPS.

Other equities analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, November 1st. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 8th. Chardan Capital assumed coverage on shares of Tvardi Therapeutics in a research report on Tuesday, October 20th. They set a “buy” rating on the stock. BTIG Research lowered their target price on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.40.

Read Our Latest Stock Report on Tvardi Therapeutics

Tvardi Therapeutics Price Performance

TVRD opened at $1.04 on Tuesday. Tvardi Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $5.69. The firm’s fifty day moving average price is $1.18 and its two-hundred day moving average price is $2.55. The company has a market capitalization of $13.90 million, a P/E ratio of -0.39 and a beta of 0.37.

Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last issued its earnings results on Friday, November 13th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.03.

Institutional Trading of Tvardi Therapeutics

A number of large investors have recently bought and sold shares of TVRD. GSA Capital Partners LLP bought a new position in shares of Tvardi Therapeutics during the second quarter valued at $34,000. Susquehanna International Group LLP acquired a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at $63,000. Finally, BlackRock Inc. acquired a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at $181,000. 44.66% of the stock is currently owned by institutional investors.

Tvardi Therapeutics Company Profile

(Get Free Report)

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and fibrotic diseases. The company’s research focuses on STAT3, a protein involved in processes that can contribute to tumor growth and fibrosis. Its lead drug candidate, TTI-101, is an oral small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. Tvardi is also advancing additional drug candidates based on its STAT3 research platform. Headquartered in The Woodlands, Texas, Tvardi is focused on research and clinical development; its investigational candidates are not established commercial products.

Featured Articles

Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.